药物性肝损伤临床与组织病理学特点

doi:10.3969/j.issn.1672-5069.2019.02.003

实用肝脏病杂志 ›› 2019, Vol. 22 ›› Issue (2): 160-163.doi: 10.3969/j.issn.1672-5069.2019.02.003

药物性肝损伤临床与组织病理学特点

刘立伟,赵新颜

100050 北京市首都医科大学附属北京友谊医院肝病研究中心/国家消化系统疾病临床医学研究中心

收稿日期:2019-01-03 出版日期:2019-03-10 发布日期:2019-03-19
通讯作者: 赵新颜,E-mail: zhao_xinyan@ccmu.edu.cn
作者简介:刘立伟,女,26岁,硕士研究生。E-mail:liuliweilc@163.com

Clinicopathological features of drug-induced liver injury

Liu Liwei, Zhao Xinyan

Liver Research Center and National Clinical Research Center for Digestive Disease,Friendship Hospital,Capital Medical University,Beijing 100050,China

Received:2019-01-03 Online:2019-03-10 Published:2019-03-19

摘要/Abstract

关键词: 药物性肝损伤, 病理学, 草药和膳食补充剂

Key words: Drug-induced liver injury, Pathology, Herbals and dietary supplements

刘立伟,赵新颜. 药物性肝损伤临床与组织病理学特点[J]. 实用肝脏病杂志, 2019, 22(2): 160-163.

Liu Liwei, Zhao Xinyan. Clinicopathological features of drug-induced liver injury[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 160-163.

[1] Alempijevic T,Zec S,Milosavljevic T.Drug-induced liver injury:Do we know everything World [J] Hepatol,2017,9(10):491-502.
[2] Yu Y,Mao Y,Chen C,et al.CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int,2017,11(3):221-241.
[3] Church R J,Kullak-Ublick G A,Aubrecht J,et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury:An international collaborative effort. Hepatology (Baltimore,Md.),2018[ahead of print].
[4] Kullak-Ublick G A,Andrade R J,Merz M,et al. Drug-induced liver injury:recent advances in diagnosis and risk assessment. Gut,2017,66(6):1154-1164.
[5] Chalasani N P,Hayashi P H,Bonkovsky H L,et al.ACG Clinical Guideline:the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol,2014,109(7):950-966,967.
[6] Fontana R J,Seeff L B,Andrade R J,et al.Standardization of nomenclature and causality assessment in drug-induced liver injury:summary of a clinical research workshop. Hepatology,2010,52(2):730-742.
[7] 杨瑞园,赵新颜. 肝组织病理学检查在药物性肝损伤诊治中的意义. 临床肝胆病杂志,2018,34(6):1172-1175.
[8] Brewer C T,Chen T.Hepatotoxicity of herbal supplements mediated by modulation of cytochrome P450. Int J Mol Sci,2017,18(11):1423-1427.
[9] Benichou C.Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol,1990,11(2):272-276.
[10] Sundaram V,Bjornsson E S.Drug-induced cholestasis. Hepatol Commun,2017,1(8):726-735.
[11] Bjornsson E S,Jonasson J G.Drug-induced cholestasis. Clin Liver Dis,2013,17(2):191-209.
[12] Popper HRE,Cardiol D.Drug-induced liver disease:A penalty for progress. Arch Intern Med,1965,115:128-136.
[13] Kleiner D E,Chalasani N P,Lee W M,et al.Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology (Baltimore,Md.),2014,59(2):661-670.
[14] Kleiner D E.Recent advances in the histopathology of drug-induced liver injury. Surg Pathol Clin,2018,11(2):297-311.
[15] Kleiner D E.The histopathological evaluation of drug-induced liver injury. Histopathology,2017,70(1):81-93.
[16] Zimmerman H J.The spectrum of hepatotoxicity. Perspect Biol Med,1968,12(1):135-161.
[17] 于乐成,茅益民,陈成伟. 药物性肝损伤诊治指南. 实用肝脏病杂志,2017,20(2):257-274.
[18] Newsome P N,Hussain M A,Theise N D.Hepatic oval cells: helping redefine a paradigm in stem cell biology. Curr Top Dev Biol,2004,61:1-28.
[19] Than N N,Newsome P N.Stem cells for liver regeneration. QJM Mon J Assoc Phys,2014,107(6):417-421.
[20] Sebode M,Schulz L,Lohse A W.“Autoimmune(-Like)” drug and herb induced liver injury:New insights into molecular pathogenesis. Int J Mol Sci,2017,18(9):842-846.
[21] de Boer Y S,Kosinski A S,Urban T J,et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol,2017,15(1):103-112.
[22] Bjornsson E,Talwalkar J,Treeprasertsuk S,et al.Drug-induced autoimmune hepatitis:clinical characteristics and prognosis. Hepatology (Baltimore,Md.),2010,51(6):2040-2048.
[23] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015). 临床肝胆病杂志,2016,32(1):9-22.
[24] Suzuki A,Brunt E M,Kleiner D E,et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury. Hepatology,2011,54(3):931-939.
[25] Reau N S,Jensen D M.Vanishing bile duct syndrome. Clin Liver Dis,2008,12(1):203-217.
[26] Moradpour D,Altorfer J,Flury R,et al.Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis. Hepatology,1994,20(6):1437-1441.
[27] Geubel A P,Sempoux C L.Drug and toxin-induced bile duct disorders. J Gastroenterol Hepatol,2000,15(11):1232-1238.
[28] Desmet V J.Vanishing bile duct syndrome in drug-induced liver disease. J Hepatol,1997,26(Suppl 1):31-35.
[29] Kleiner D E.Drug-induced liver injury:The hepatic pathologist's approach. Gastroenterol Clin North Am,2017,46(2):273-296.
[30] Bonkovsky H L,Kleiner D E,Gu J,et al.Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology,2017,65(4):1267-1277.
[31] Navarro V J,Khan I,Bjornsson E,et al.Liver injury from herbal and dietary supplements. Hepatology (Baltimore,Md.),2017,65(1):363-373.
[32] Medina-Caliz I,Garcia-Cortes M,Gonzalez-Jimenez A,et al.Herbal and dietary supplement-induced liver injuries in the spanish DILI registry. Clin Gastroenterol Hepatol,2018,16(9):1495-1502.
[33] Wang Y,Wang L,Saxena R,et al. Clinicopathological features of He Shou Wu-induced liver injury:This ancient anti-aging therapy is not liver-friendly. Liver Int,2018[ahead of print].

药物性肝损伤临床与组织病理学特点

Clinicopathological features of drug-induced liver injury

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴欣, 郭杨志, 杜霄壤, 吴孟晋, 朱云, 冯兴中. 75例中药诱导的肝损伤患者临床特征分析*[J]. 实用肝脏病杂志, 2019, 22(5): 668-671.
[2]	张梅, 石秀英, 李林娟, 薛亚妮. 肝源性糖尿病患者肝组织干扰素诱导蛋白-10表达变化*[J]. 实用肝脏病杂志, 2019, 22(5): 688-691.
[3]	王刚, 赵洪波, 朱亚玲, 蒋保三, 张越美, 刁勇. 基于数据库分析肝细胞癌细胞XPO5基因水平变化及其临床意义*[J]. 实用肝脏病杂志, 2019, 22(5): 724-727.
[4]	蒋奕,刘冰. 慢性乙型肝炎与慢性丙型肝炎患者临床和肝组织病理学特征分析[J]. 实用肝脏病杂志, 2019, 22(2): 188-191.
[5]	林兰,沈敏,阮健文. 自身免疫性肝炎患者肝组织程序性死亡受体1表达及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 204-207.
[6]	黄春洋,单晶,廖慧钰,黄云丽,韩莹,张小丹,杜晓菲,任美欣,边新渠,刘燕敏. 甲基强的松龙治疗药物性肝损伤患者临床及实验室特点分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 208-211.
[7]	吴秀欣,张惠勇,张凯. 抗结核药物所致肝损伤患者血浆MiRNA-4284水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 212-215.
[8]	宋芳娇,朱冰,吕飒,田华,王海波,辛绍杰,游绍莉. 314例药物性肝衰竭患者临床特征分析^*[J]. 实用肝脏病杂志, 2019, 22(2): 216-219.
[9]	王虎明,樊东升,徐杰,刘险峰,周宁,丽敏,包娜娜. 肝细胞癌患者癌组织miRNA-30c水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(2): 248-251.
[10]	孙文静, 陈东风. UCAM和Maria诊断标准用于评估1352例中国人药物性肝损伤文献分析[J]. 实用肝脏病杂志, 2018, 21(6): 881-884.
[11]	张海涛, 孙浩, 李凯, 许发功, 蒋汉梅. 胆汁反流性胃炎患者幽门螺杆菌感染及其胃粘膜病理学表现研究^*[J]. 实用肝脏病杂志, 2018, 21(6): 967-970.
[12]	佟欣, 樊华. 双环醇治疗胃癌化疗所致肝损伤患者肝功能指标的变化[J]. 实用肝脏病杂志, 2018, 21(4): 625-626.
[13]	刘聪, 王婷婷, 左莉莉, 甄萍. 近3年住院患者药物性肝损伤状况调查[J]. 实用肝脏病杂志, 2018, 21(4): 639-640.
[14]	纪元. 隐源性非硬化性门脉高压症患者临床和肝组织病理学表现[J]. 实用肝脏病杂志, 2018, 21(3): 325-328.
[15]	张金莲, 蔡兆根, 吴琼, 秦燕子, 王梦慧, 董修芹. 肝细胞癌患者血清和肝组织microRNAlet-7水平及其与临床预后的关系*[J]. 实用肝脏病杂志, 2018, 21(3): 435-438.